Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07617493 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of ICP-B208 in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Jun 2026 to Jul 3, 2026 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jun 2026 to Jul 3, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors
Trial Details
NCT Number NCT07617493
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 539 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov